[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74:229−263

doi: 10.3322/caac.21834
[2]

Wang T, Nelson RA, Bogardus A, Grannis FW Jr. 2010. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116:1518−1525

doi: 10.1002/cncr.24871
[3]

Woodard GA, Jones KD, Jablons DM. 2016. Lung cancer staging and prognosis. In Lung Cancer, ed. Reckamp KL. Cham: Springer. pp. 47−75 doi: 10.1007/978-3-319-40389-2_3
[4]

Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, et al. 2011. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 140:1494−1502

doi: 10.1378/chest.10-3279
[5]

Huang J, Deng Y, Tin MS, Lok V, Ngai CH, et al. 2022. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest 161:1101−1111

doi: 10.1016/j.chest.2021.12.655
[6]

Li C, Lei S, Ding L, Xu Y, Wu X, et al. 2023. Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal 136:1583−1590

doi: 10.1097/CM9.0000000000002529
[7]

Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. 2021. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nature Reviews Clinical Oncology 18:135−151

doi: 10.1038/s41571-020-00432-6
[8]

Bonney A, Malouf R, Marchal C, Manners D, Fong KM, et al. 2022. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. The Cochrane Database of Systematic Reviews 8:CD013829

doi: 10.1002/14651858.CD013829.pub2
[9]

Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, et al. 2013. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 80:45−49

doi: 10.1016/j.lungcan.2013.01.002
[10]

Wu LX, Li XF, Chen HF, Zhu YC, Wang WX, et al. 2019. Combined detection of CEA and CA125 for the diagnosis for lung cancer: a meta-analysis. Cellular and Molecular Biology 64:67−70

doi: 10.14715/cmb/2017.64.15.11
[11]

Xu CM, Luo YL, Li S, Li ZX, Jiang L, et al. 2019. Multifunctional neuron-specific enolase: its role in lung diseases. Bioscience Reports 39:BSR20192732

doi: 10.1042/BSR20192732
[12]

Wang L, Wang D, Zheng G, Yang Y, Du L, et al. 2016. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. The International Journal of Biological Markers 31:e80−e87

doi: 10.5301/jbm.5000177
[13]

Tan EM, Zhang J. 2008. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunological Reviews 222:328−340

doi: 10.1111/j.1600-065X.2008.00611.x
[14]

Du Q, Yu R, Wang H, Yan D, Yuan Q, et al. 2018. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. The Clinical Respiratory Journal 12:2020−2028

doi: 10.1111/crj.12769
[15]

Deng X, Ma N, He J, Xu F, Zou G. 2024. The role of TGFBR3 in the development of lung cancer. Protein & Peptide Letters 31:491−503

doi: 10.2174/0109298665315841240731060636
[16]

Li CL, Ma XY, Yi P. 2025. The role of immunotherapy in lung cancer treatment: current strategies, future directions, and insights into metastasis and immune microenvironment. Current Gene Therapy 25:453−466

doi: 10.2174/0115665232340926241105064739
[17]

Luo H, Wei W, Ye Z, Zheng J, Xu RH. 2021. Liquid biopsy of methylation biomarkers in cell-free DNA. Trends in Molecular Medicine 27:482−500

doi: 10.1016/j.molmed.2020.12.011
[18]

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, et al. 2017. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer 17:223−238

doi: 10.1038/nrc.2017.7
[19]

Tébar-Martínez R, Martín-Arana J, Gimeno-Valiente F, Tarazona N, Rentero-Garrido P, et al. 2023. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treatment Reviews 119:102595

doi: 10.1016/j.ctrv.2023.102595
[20]

Leal A, Sidransky D, Brait M. 2020. Tissue and cell-free DNA-based epigenomic approaches for cancer detection. Clinical Chemistry 66:105−116

doi: 10.1373/clinchem.2019.303594
[21]

Jiang P, Sun K, Tong YK, Cheng SH, Cheng THT, et al. 2018. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 115:E10925−E10933

doi: 10.1073/pnas.1814616115
[22]

Ding SC, Dennis Lo YM. 2022. Cell-free DNA fragmentomics in liquid biopsy. Diagnostics 12:978

doi: 10.3390/diagnostics12040978
[23]

Dennis Lo YM, Han DSC, Jiang P, Chiu RWK. 2021. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science 372:eaaw3616

doi: 10.1126/science.aaw3616
[24]

Song P, Wu LR, Yan YH, Zhang JX, Chu T, et al. 2022. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering 6:232−245

doi: 10.1038/s41551-021-00837-3
[25]

Breiling A, Lyko F. 2015. Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics & Chromatin 8:24

doi: 10.1186/s13072-015-0016-6
[26]

Ibrahim J, Peeters M, Van Camp G, Op de Beeck K. 2023. Methylation biomarkers for early cancer detection and diagnosis: current and future perspectives. European Journal of Cancer 178:91−113

doi: 10.1016/j.ejca.2022.10.015
[27]

Krueger F, Kreck B, Franke A, Andrews SR. 2012. DNA methylome analysis using short bisulfite sequencing data. Nature Methods 9:145−151

doi: 10.1038/nmeth.1828
[28]

Guo P, Zheng H, Li Y, Li Y, Xiao Y, et al. 2023. Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA. Clinical Epigenetics 15:2

doi: 10.1186/s13148-022-01420-6
[29]

Hubers AJ, Heideman DAM, Burgers SA, Herder GJM, Sterk PJ, et al. 2015. DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. British Journal of Cancer 112:1105−1113

doi: 10.1038/bjc.2014.636
[30]

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, et al. 2017. A panel of novel detection and prognostic methylated DNA markers in primary non–small cell lung cancer and serum DNA. Clinical Cancer Research 23:7141−7152

doi: 10.1158/1078-0432.CCR-17-1222
[31]

Xu W, Lu J, Zhao Q, Wu J, Sun J, et al. 2019. Genome-wide plasma cell-free DNA methylation profiling identifies potential biomarkers for lung cancer. Disease Markers 2019:4108474

doi: 10.1155/2019/4108474
[32]

Chen S, Zhou Y, Chen Y, Gu J. 2018. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34:i884−i890

doi: 10.1093/bioinformatics/bty560
[33]

Krueger F, Andrews SR. 2011. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27:1571−1572

doi: 10.1093/bioinformatics/btr167
[34]

Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, et al. 2011. Scikit-learn: machine learning in Python. Journal of Machine Learning Research 12:2825−2830
[35]

Li X, Yang T, Li CS, Song Y, Wang D, et al. 2020. Polymerase chain reaction - surface-enhanced Raman spectroscopy (PCR-SERS) method for gene methylation level detection in plasma. Theranostics 10:898−909

doi: 10.7150/thno.30204
[36]

Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, et al. 2011. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clinical Cancer Research 17:4494−4503

doi: 10.1158/1078-0432.CCR-10-3436
[37]

Mohammed F, Baydaa Abed Hussein A, Ahmed T. 2022. Evaluation of methylation panel in the promoter region of p16INK4a, RASSF1A, and MGMT as a biomarker in sputum for lung cancer. Archives of Razi Institute 77:1075−1081

doi: 10.22092/ARI.2022.357985.2131
[38]

Hung CS, Wang SC, Yen YT, Lee TH, Wen WC, et al. 2018. Hypermethylation of CCND2 in lung and breast cancer is a potential biomarker and drug target. International Journal of Molecular Sciences 19:3096

doi: 10.3390/ijms19103096
[39]

Zhang Y, Wang R, Song H, Huang G, Yi J, et al. 2011. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Letters 303:21−28

doi: 10.1016/j.canlet.2010.12.011
[40]

Chang HT, Wang PH, Chen WF, Lin CJ. 2022. Risk assessment of early lung cancer with LDCT and health examinations. International Journal of Environmental Research and Public Health 19:4633

doi: 10.3390/ijerph19084633
[41]

Maller B, Tanvetyanon T. 2022. Emerging approaches to complement low-dose computerized tomography for lung cancer screening: a narrative review. Cureus 14:e27309

doi: 10.7759/cureus.27309
[42]

Chen M, Zhao H. 2019. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Human Genomics 13:34

doi: 10.1186/s40246-019-0220-8
[43]

Vaisvila R, Ponnaluri VKC, Sun Z, Langhorst BW, Saleh L, et al. 2021. Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. Genome Research 31:1280−1289

doi: 10.1101/gr.266551.120
[44]

Ullah A, Razzaq A, Alfaifi MY, Elbehairi SEI, Menaa F, et al. 2024. Sanguinarine attenuates lung cancer progression via oxidative stress-induced cell apoptosis. Current Molecular Pharmacology 17:e18761429269383

doi: 10.2174/0118761429269383231119062233
[45]

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, et al. 2020. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology 31:745−759

doi: 10.1016/j.annonc.2020.02.011
[46]

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, et al. 2018. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563:579−583

doi: 10.1038/s41586-018-0703-0
[47]

Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, et al. 2021. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications 12:5060

doi: 10.1038/s41467-021-24994-w
[48]

Xue R, Li X, Yang L, Yang M, Zhang B, et al. 2024. Evaluation and integration of cell-free DNA signatures for detection of lung cancer. Cancer Letters 604:217216

doi: 10.1016/j.canlet.2024.217216
[49]

Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, et al. 2022. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40:1537−1549.e12

doi: 10.1016/j.ccell.2022.10.022
[50]

Wang X, Chen Y, Ma C, Bi L, Su Z, et al. 2025. Current advances and future prospects of blood-based techniques for identifying benign and malignant pulmonary nodules. Critical Reviews in Oncology/Hematology 207:104608

doi: 10.1016/j.critrevonc.2024.104608
[51]

Liang W, Tao J, Cheng C, Sun H, Ye Z, et al. 2024. A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules. Cell Reports Medicine 5:101750

doi: 10.1016/j.xcrm.2024.101750